(Q42619190)

3 November 2017

title

Tiagabine for social anxiety disorder (English)

1 reference

3 November 2017

Boadie W Dunlop

1

0 references

Philip Ninan

object named as

Philip T Ninan

6

0 references

author name string

Laszlo Papp

2

1 reference

3 November 2017

Steven J Garlow

3

1 reference

3 November 2017

Paul S Weiss

4

1 reference

3 November 2017

Bettina T Knight

5

1 reference

3 November 2017

publication date

1 June 2007

1 reference

3 November 2017

published in

Human Psychopharmacology

1 reference

3 November 2017

volume

22

1 reference

3 November 2017

issue

4

1 reference

3 November 2017

page(s)

241-244

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

3 November 2017

cites work

1 reference

21 January 2018

1 reference

The evidence-based pharmacological treatment of social anxiety disorder

21 January 2018

1 reference

7 January 2021

Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale

1 reference

7 January 2021

Pharmacotherapy of social phobia.

1 reference

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

7 January 2021

[3H]tiagabine binding to GABA uptake sites in human brain

1 reference

7 January 2021

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

1 reference

7 January 2021

The lifelong course of social anxiety disorder: a clinical perspective.

1 reference

7 January 2021

Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey

1 reference

7 January 2021

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

7 January 2021

Social phobia in a population-based female adolescent twin sample: co-morbidity and associated suicide-related symptoms

1 reference

7 January 2021

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

1 reference

7 January 2021

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.

1 reference

7 January 2021

An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder

1 reference

7 January 2021

The measurement of disability.

1 reference

7 January 2021

Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults

1 reference

7 January 2021

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

1 reference

7 January 2021

An open trial of topiramate in the treatment of generalized social phobia.

1 reference

7 January 2021

The impact of social phobia on quality of life.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.846

1 reference

3 November 2017

1 reference